GLP-1 Price Guide Compare prices
Safety · June 1, 2026

FDA's 2026 GLP-1 Compounding Framework Explained

Three major regulatory changes in 2026 affect compounded GLP-1 telehealth. What patients need to know.

Safety & RegulationJune 1, 2026Editorial

Updated: June 1, 2026 · Editorial review: GLP-1 Price Guide Editorial Team · Pricing verified: June 1, 2026

Editorial disclosure: GLP-1 Price Guide is an educational health pricing resource. We do not provide medical advice, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Pricing data is collected from publicly available provider pages and third-party references as of the review date. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page.
Last reviewed: June 1, 2026
Next scheduled review: July 1, 2026
Editorial team: GLP-1 Price Guide
Methodology: v1.0 pricing framework

See full analysis on compounded GLP-1 regulations 2026. Summary:

  1. Shortage resolution (2024-2025). FDA confirmed semaglutide and tirzepatide shortages resolved. Shortage-era allowances ended.
  2. 503B bulks list exclusion proposal (April 2026). FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. Not yet finalized.
  3. Marketing enforcement. Increased FDA scrutiny on FDA-approval claims, brand equivalence claims, and research-peptide vendors.

Sources reviewed

  • Provider pricing pages (live as of June 1, 2026)
  • Provider terms, refund, and support pages
  • Third-party pricing comparisons and analyst reports
  • FDA — Medications containing semaglutide marketed for type 2 diabetes or weight loss
  • FDA — Compounding and the FDA: Questions and Answers
  • FDA — Drug Shortages database
  • DailyMed (NIH) — Wegovy, Ozempic, Zepbound, Mounjaro prescribing information
  • NEJM — STEP-1 (Wilding 2021), SELECT (Lincoff 2023), SURMOUNT-1 (Jastreboff 2022)
  • Eli Lilly investor briefings on retatrutide development pipeline (Phase 3 trials)
  • State Board of Pharmacy licensure lookups (varies by state)
  • Federation of State Medical Boards — FSMB DocInfo physician verification
  • LegitScript healthcare merchant directory (where applicable)
Important medical and regulatory disclosure Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Price Guide does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.

Frequently asked questions

What does this guide cover about fda's 2026 glp-1 compounding framework explained?
This page explains fda's 2026 glp-1 compounding framework explained and how it affects the true monthly cost of a compounded GLP-1 program, so you can compare providers on more than the advertised starter price.
How does this affect what I actually pay?
Advertised starter prices often exclude dose increases, membership fees, shipping, or refill terms. Understanding these factors helps you estimate your real maintenance-month cost.
What is a transparent, predictable option?
Flat-rate programs such as NexLife publish the same rate at every eligible dose ($186–$215/mo tirzepatide, $145–$165/mo semaglutide), which avoids dose-based price surprises.
Are compounded GLP-1 medications FDA-approved?
Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products. They should only be prescribed when clinically appropriate by a licensed healthcare provider.
How is the pricing here verified?
Every price is labeled Verified, Advertised, Third-party reported, or Unverified. Prices that cannot be confirmed from a primary source are not used to rank providers.

Related pricing tools & guides